ClinicalTrials.gg
Status unknownNCT04152369ESBLUpdated Feb 20, 2020

"Peri-operative Antimicrobial Prophylaxis in Patients With Asymptomatic Bacteriuria of Enterobacteriacae ESBL+ Origin"

An interventional study of Anti-microbial prophylaxis for an endourological procedure or ESWL in Antimicrobial Prophylaxis and Asymptomatic Bacteriuria, sponsored by Military Institute od Medicine National Research Institute. Status unknown at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-20.

Sponsored by Military Institute od Medicine National Research Institute · Not applicable, Interventional, and Health services research

The sponsor has not verified this record recently (last verified Feb 2020), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 3 years 3 months after the study started (first participant enrolled Jul 2016, registered Oct 2019).
Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of the study is to determine optimal safe duration of antibiotic prophylaxis in patients undergoing endourological procedures and ESWL, presenting with asymptomatic bacteriuria caused by multi-drug resistant bacterial strains. In this study we compare safety and efficacy of a one-day vs. three-day AMP (Antimicrobial Prophylaxis) in the above mentioned group of patients.

Read the detailed description

Patients with positive urine culture with Enterobacteriacae ESBL + resistance mechanism upon admission for endourological procedure or ESWL were subjected to body temperature measurement and laboratory tests: smear from the anus towards the presence of alarm pathogens, urinalysis, control urine culture, blood count, CRP (C-reactive protein), procalcitonin (PCT). After confirming the occurrence of asymptomatic bacteriuria, the patients were randomized to two groups - a one-day and three-day period lasting perioperative antibiotic prophylaxis. In both groups on the following day after the procedure (24 hours after the procedure) and after 7 days after the procedure, laboratory tests and body temperature measurements were performed.

02

Conditions studied

  • Antimicrobial Prophylaxis
  • Asymptomatic Bacteriuria

Browse trials for

Keywords

  • ESBL+
  • Antimicrobial prophylaxis
03

In context

Bacteriuria

51 studies on the registry are indexed under Bacteriuria; 3 are open to participants now.

This study's planned enrollment of 70 is below the median of 100 across 37 interventional studies indexed under Bacteriuria.

Browse Bacteriuria studies →

Lead sponsor

Military Institute od Medicine National Research Institute is the lead sponsor of 45 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ESBL+ asymptomatic bacteriuria
  • assigned for endourological procedure
  • normal CRP, PCT and WBC
  • patient's consent

Exclusion criteria

Exclusion Criteria:

  • urinary tract infection
  • raised levels of CRP, PCT, WBC
  • fever
  • non ESBL+ bacteriuria
  • inability to consent
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
70 participants (estimated)

Study arms

  • Active comparator
    24 hour prophylaxis

    In this group patients received a AMP for the day of the procedure

    Procedure: Anti-microbial prophylaxis for an endourological procedure or ESWL

  • Active comparator
    72 hour prophylaxis

    In this group patients received a AMP one day prior, on the day of the procedure and the following day.

    Procedure: Anti-microbial prophylaxis for an endourological procedure or ESWL

Interventions

  • ProcedureAnti-microbial prophylaxis for an endourological procedure or ESWL

    anti-microbial prophylaxis according to urine culture results

06

What researchers measure

Primary outcomes

  1. Safety and efficacy of perioperative antibiotic prophylaxis in patients with Enterobacteriacae ESBL+ urinary tract colonization undergoing endourological procedures and ESWL (Extracorporeal Shock Wave Lithotripsy).

    To determine if a 1-day perioperative antibiotic prophylaxis is as safe and effective as 3-day perioperative antibiotic prophylaxis in patients with Enterobacteriacae ESBL+ urinary tract colonization undergoing endourological procedures. This conclusion will be based on measurements of CRP \[mg/dl\] as follows: one day prior to procedure, one day post and 7 days after the procedure. The data will be statistically analyzed.

    Time frame: 7 days

  2. Safety and efficacy of perioperative antibiotic prophylaxis in patients with Enterobacteriacae ESBL+ urinary tract colonization undergoing endourological procedures and ESWL (Extracorporeal Shock Wave Lithotripsy).

    To determine if a 1-day perioperative antibiotic prophylaxis is as safe and effective as 3-day perioperative antibiotic prophylaxis in patients with Enterobacteriacae ESBL+ urinary tract colonization undergoing endourological procedures. This conclusion will be based on measurements of WBC level \[x 10\^9/l\] as follows: one day prior to procedure, one day post and 7 days after the procedure. The data will be statistically analyzed.

    Time frame: 7 days

  3. Safety and efficacy of perioperative antibiotic prophylaxis in patients with Enterobacteriacae ESBL+ urinary tract colonization undergoing endourological procedures and ESWL (Extracorporeal Shock Wave Lithotripsy).

    To determine if a 1-day perioperative antibiotic prophylaxis is as safe and effective as 3-day perioperative antibiotic prophylaxis in patients with Enterobacteriacae ESBL+ urinary tract colonization undergoing endourological procedures. This conclusion will be based on measurements of levels of prokalcytonin \[ng/ml\] as follows: one day prior to procedure, one day post and 7 days after the procedure. The data will be statistically analyzed.

    Time frame: 7 days

  4. Safety and efficacy of perioperative antibiotic prophylaxis in patients with Enterobacteriacae ESBL+ urinary tract colonization undergoing endourological procedures and ESWL (Extracorporeal Shock Wave Lithotripsy).

    To determine if a 1-day perioperative antibiotic prophylaxis is as safe and effective as 3-day perioperative antibiotic prophylaxis in patients with Enterobacteriacae ESBL+ urinary tract colonization undergoing endourological procedures. This conclusion will be based on measurements of body temperature \[Celsius\] as follows: one day prior to procedure, one day post and 7 days after the procedure. The data will be statistically analyzed.

    Time frame: 7 days

07

Study locations

1 of 1 sites recruiting
  • Military Institue of Medicine
    Warsaw, Mazowieckie 04-141, Poland
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2016 (actual). Primary completion is estimated for Jun 2020, 47 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2019
First posted
Nov 5, 2019
StartActual
Jul 15, 2016
Primary completionEst.
Jun 30, 2020
CompletionEst.
Jun 30, 2020
Last update
Feb 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04152369
Lead sponsor
Military Institute od Medicine National Research Institute
Responsible party
Marcin Radko (Principal Investigator, Military Institute od Medicine National Research Institute) — Principal investigator
First posted
Nov 5, 2019
Start date
Jul 15, 2016
Primary completion
Jun 30, 2020 (estimated)
Completion
Jun 30, 2020 (estimated)
Last update
Feb 20, 2020

Study contacts

Marcin A Radko, MD
Contact
mradko@wim.mil.pl
+48603768924
Marcin A Radko, MD
principal investigator · Military Institute of Medicine
Henryk Zieliński, Professor
study chair · Military Institute of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion